The government of Canada is preparing for the planned recreational legalization of cannabis next year with new rounds of funding.
On Tuesday (October 31) Health Canada announced it would dedicate new funds for public education, awareness, and surveillance, raising the budget to $46 million.
The current plan is to use this money for a public campaign over the next five years. The campaign will most likely target prohibition for people under the required legal age in Canada and impaired driving related to cannabis. Canada’s chief public health officer, Dr. Theresa Tam said the proposed campaign will be evidence-based and will help minors understand the “health impacts around cannabis use.”
Parliamentary secretary to the minister of health, Bill Blair said the government wants Canadians to have a clear and factual understanding of the impact of cannabis. According to the government, the campaign will implement social media efforts in addition to advertising and “interactive events.”
“Subject to Parliamentary approval, the Government will expand its public education campaign to include information on the new laws, so Canadians will know what to expect in July 2018,” Health Canada wrote in their statement.

Report shows Health Canada getting “bulk” of federal funds for cannabis plans

A new report from the Financial Post indicates Health Canada will get $432 million over a five year period set to help manage all needs related to the legalization of recreational cannabis.
Health Canada told the Financial Post it would use the funding for “a new regulatory approach, including licensing and inspection, compliance and enforcement, monitoring and research, as well as a national public education and awareness campaign, tracking systems and program support.”
This year the Canadian regulatory agency has faced an influx of cannabis companies seeking licenses to grow and sell product respectively.

Impaired driving still a concern with cannabis users

In July INN spoke with Jonathan Zaid, founder and executive director of the Canadians for Fair Access to Medical Marijuana (CFAM) group about the way the current law could not be efficient enough for medical cannabis users.
“We don’t want to see anybody driving impaired or any kind of unsafe driving, but at the same time, we want to see a way that would consider the evidence that does or does not exist,” Zaid said.
CFAM authored a research report into the current laws in Canada and how they could impact cannabis patients.
“Within the context of medical use, there are certain considerations such as both administration and the education patients receive from physicians that differ in how impairment may actually exist in the real world,” Zaid told INN.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less